Huntington disease: Cerebrospinal fluid and MRI biomarkers for prodromal HD

@article{Chase2015HuntingtonDC,
  title={Huntington disease: Cerebrospinal fluid and MRI biomarkers for prodromal HD},
  author={Alex Chase},
  journal={Nature Reviews Neurology},
  year={2015},
  volume={11},
  pages={245-245}
}
  • A. Chase
  • Published 21 April 2015
  • Biology, Medicine
  • Nature Reviews Neurology
Cerebrospinal fluid and MRI biomarkers for prodromal HD Two recently published studies have described new biomarkers for measuring Huntington disease (HD) activity in people who carry the pathogenetic mutation, but do not yet show symptoms. These results could improve the monitoring of patients with so-called prodromal HD, and thereby facilitate clinical trials. The accumulation of mutant huntingtin protein is the main histopathological correlate of HD, but it has been very difficult to detect… 

References

SHOWING 1-2 OF 2 REFERENCES
Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington's disease patients.
TLDR
It is demonstrated that mHTT can be quantified in CSF from HD patients using the described SMC m HTT immunoassay, and the level ofmHTT detected is associated with proximity to disease onset and diminished cognitive and motor function.
T1ρ imaging in premanifest Huntington disease reveals changes associated with disease progression
TLDR
The potential value of T1ρ relaxation to detect pathological changes in premanifest HD (preHD) relative to other quantitative relaxation parameters is investigated.